@amirbastawrous @DCRjournal @JISBMD @ConorDelaneyMD @justinmaykel @KarimAlavi @KyleCologne @dubaicolorectal @debby_keller @SeanLangenfeld @FicheraAlessand @ValSimianu @ColonCancerDoc @ScottRSteeleMD Luckily never had one. Others have reported as high as 8%
RT @borjadelacy: #TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @Anton…
RT @SurgEndosc: https://t.co/q4YYNpd0pc Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal c…
RT @SurgEndosc: https://t.co/q4YYNpd0pc Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal c…
RT @SurgEndosc: https://t.co/q4YYNpd0pc Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal c…
https://t.co/q4YYNpd0pc Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer #Surgery #SAGES #EAES
RT @SurgEndosc: https://t.co/q4YYNpd0pc Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal c…
RT @SurgEndosc: https://t.co/q4YYNpd0pc Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal c…
RT @SurgEndosc: https://t.co/q4YYNpd0pc Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal c…
RT @SurgEndosc: https://t.co/q4YYNpd0pc Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal c…
RT @SurgEndosc: https://t.co/q4YYNpd0pc Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal c…
RT @SurgEndosc: https://t.co/q4YYNpd0pc Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal c…
RT @SurgEndosc: https://t.co/q4YYNpd0pc Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal c…
RT @SWexner: Excellent series update in @SurgEndosc from our @JAmCollSurg publication https://t.co/K61JTNOMlf https://t.co/JLq8WkzgLD
RT @borjadelacy: #TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @Anton…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/OY…
RT @AECP_FAECP: Y también parece que el #TaTME (bien indicado y realizado) es seguro oncológicamente #colorectalsurgery https://t.co/opllG…
RT @salo75: Retweeted Borja de Lacy (@borjadelacy): #TaTME: our preferred approach for rectal cancer, even for T4 tumors!... https://t.co/…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/OY…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/OY…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/OY…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/OY…
RT @SWexner: Excellent series update in @SurgEndosc from our @JAmCollSurg publication https://t.co/K61JTNOMlf https://t.co/JLq8WkzgLD
TaTME https://t.co/tqK7Ycn1Xy
RT @borjadelacy: #TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @Anton…
RT @borjadelacy: #TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @Anton…
RT @FezaRemziMD: ✊ results & ?benefit of #TaTME.A concern;what isNOT being reported 🌎in adaption #TaTME. #patient may be paying >price with…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/U7…
RT @SWexner: Excellent series update in @SurgEndosc from our @JAmCollSurg publication https://t.co/K61JTNOMlf https://t.co/JLq8WkzgLD
RT @borjadelacy: #TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @Anton…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/OY…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/U7…
RT @salo75: Retweeted Borja de Lacy (@borjadelacy): #TaTME: our preferred approach for rectal cancer, even for T4 tumors!... https://t.co/…
Retweeted Borja de Lacy (@borjadelacy): #TaTME: our preferred approach for rectal cancer, even for T4 tumors!... https://t.co/a4508DtASk
RT @borjadelacy: #TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @Anton…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/U7…
RT @borjadelacy: #TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @Anton…
RT @borjadelacy: #TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @Anton…
RT @FezaRemziMD: ✊ results & ?benefit of #TaTME.A concern;what isNOT being reported 🌎in adaption #TaTME. #patient may be paying >price with…
RT @FezaRemziMD: ✊ results & ?benefit of #TaTME.A concern;what isNOT being reported 🌎in adaption #TaTME. #patient may be paying >price with…
RT @FezaRemziMD: ✊ results & ?benefit of #TaTME.A concern;what isNOT being reported 🌎in adaption #TaTME. #patient may be paying >price with…
✊ results & ?benefit of #TaTME.A concern;what isNOT being reported 🌎in adaption #TaTME. #patient may be paying >price without clear benefit https://t.co/5nxeOauN6H
RT @borjadelacy: #TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @Anton…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/U7…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/OY…
RT @borjadelacy: #TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @Anton…
RT @JJEMvanL: Teamwork continues!! @borjadelacy @AntoniodeLacy @RominaPena @macarroyave https://t.co/8c7Uq7xmx6
RT @borjadelacy: #TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @Anton…
RT @borjadelacy: #TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @Anton…
RT @borjadelacy: #TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @Anton…
RT @dr_samehhany81: TaTME continues to achieve excellent pathologic outcome with complete TME in >95% of pts @SWexner @AntoniodeLacy https:…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/OY…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/U7…
RT @borjadelacy: #TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @Anton…
RT @borjadelacy: #TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @Anton…
RT @borjadelacy: #TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @Anton…
#TaTME: our preferred approach for rectal cancer, even for T4 tumors! https://t.co/5YRar6efuv @JJEMvanL @AISChannel @AntoniodeLacy
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/OY…
RT @SWexner: Excellent series update in @SurgEndosc from our @JAmCollSurg publication https://t.co/K61JTNOMlf https://t.co/JLq8WkzgLD
RT @JJEMvanL: Teamwork continues!! @borjadelacy @AntoniodeLacy @RominaPena @macarroyave https://t.co/8c7Uq7xmx6
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/U7…
RT @SWexner: Excellent series update in @SurgEndosc from our @JAmCollSurg publication https://t.co/K61JTNOMlf https://t.co/JLq8WkzgLD
RT @SWexner: Excellent series update in @SurgEndosc from our @JAmCollSurg publication https://t.co/K61JTNOMlf https://t.co/JLq8WkzgLD
RT @SWexner: Excellent series update in @SurgEndosc from our @JAmCollSurg publication https://t.co/K61JTNOMlf https://t.co/JLq8WkzgLD
RT @SWexner: Excellent series update in @SurgEndosc from our @JAmCollSurg publication https://t.co/K61JTNOMlf https://t.co/JLq8WkzgLD
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/U7…
RT @JJEMvanL: Teamwork continues!! @borjadelacy @AntoniodeLacy @RominaPena @macarroyave https://t.co/8c7Uq7xmx6
RT @dr_samehhany81: TaTME continues to achieve excellent pathologic outcome with complete TME in >95% of pts @SWexner @AntoniodeLacy https:…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/U7…
RT @SWexner: Excellent series update in @SurgEndosc from our @JAmCollSurg publication https://t.co/K61JTNOMlf https://t.co/JLq8WkzgLD
RT @SWexner: Excellent series update in @SurgEndosc from our @JAmCollSurg publication https://t.co/K61JTNOMlf https://t.co/JLq8WkzgLD
Excellent series update in @SurgEndosc from our @JAmCollSurg publication https://t.co/K61JTNOMlf https://t.co/JLq8WkzgLD
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/U7…
RT @JJEMvanL: Teamwork continues!! @borjadelacy @AntoniodeLacy @RominaPena @macarroyave https://t.co/8c7Uq7xmx6
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/U7…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/OY…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/OY…
RT @dubaicolorectal: More evidence forward moving with ta TME https://t.co/rjxHO1Qobj
RT @JJEMvanL: Teamwork continues!! @borjadelacy @AntoniodeLacy @RominaPena @macarroyave https://t.co/8c7Uq7xmx6
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/OY…
RT @JJEMvanL: Teamwork continues!! @borjadelacy @AntoniodeLacy @RominaPena @macarroyave https://t.co/8c7Uq7xmx6
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/OY…
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/U7…
RT @dubaicolorectal: More evidence forward moving with ta TME https://t.co/rjxHO1Qobj
RT @AntoniodeLacy: Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal cancer https://t.co/OY…
RT @JJEMvanL: Teamwork continues!! @borjadelacy @AntoniodeLacy @RominaPena @macarroyave https://t.co/8c7Uq7xmx6
RT @SurgEndosc: https://t.co/q4YYNpd0pc Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal c…
RT @SurgEndosc: https://t.co/q4YYNpd0pc Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal c…
More evidence forward moving with ta TME https://t.co/rjxHO1Qobj
RT @SurgEndosc: https://t.co/q4YYNpd0pc Transanal total mesorectal excision: pathological results of 186 patients with mid and low rectal c…